How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1
What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?
How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds
Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools
Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works
Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tool
How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2
T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.
How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1
Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.
Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2
Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…